Kim et al. identified the inhibitory role of LXRα in hepatocyte autophagy by upregulating the expression of miR-34a 35, while the farnesoid X receptor/miR-34a/sirtuin 1 pathway was proposed as a potential entry point for treating NAFLD 36. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.